Teva Seeks To Draw A Line Under Opioids Litigation With Final US Settlement
State Sign-On Process Still To Play Out As Teva ‘Optimistic’ Of High Participation Rate
Teva has announced a finalized nationwide settlement over its long-running opioids litigation, signalling the start of a sign-on process for individual states, subdivisions and special districts. The company remains optimistic of a high participation rate.
You may also be interested in...
Teva is continuing to knock down one-by-one US state price fixing-claims, with the prospect of a criminal trial beginning in May next year.
Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.
Teva has all but two US states on board for its long-hoped-for nationwide settlement to resolve opioid-related claims against the firm.